Which has stronger valuation & earnings, NVAX or ZURA?

Novavax has higher revenue and earnings than Zura Bio. Novavax is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.55 $440.30M -$1.52 N/A Zura Bio N/A N/A -$99.35M -$1.13 N/A

Is NVAX or ZURA more profitable?

Zura Bio has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Zura Bio N/A -56.13% -50.15%

Which has better valuation and earnings, ZURA or ABSI?

Zura Bio has higher earnings, but lower revenue than Absci. Absci is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.13 N/A Absci $2.80M 596.96 -$115.18M -$0.80 N/A

Is ZURA or ABSI more profitable?

Zura Bio has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Zura Bio's return on equity of -56.13% beat Absci's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -56.13% -50.15% Absci -7,756.38% -61.71% -54.52%

Which has higher earnings and valuation, IMCR or ZURA?

Immunocore has higher revenue and earnings than Zura Bio. Immunocore is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunocore $430.78M 3.77 -$35.51M -$0.37 N/A Zura Bio N/A N/A -$99.35M -$1.13 N/A

Is IMCR or ZURA more profitable?

Zura Bio has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Immunocore -4.20% -4.54% -1.66% Zura Bio N/A -56.13% -50.15%

Which has preferable valuation & earnings, ZURA or INBX?

Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.13 N/A Inhibrx Biosciences N/A N/A -$140.05M -$8.88 N/A

Is ZURA or INBX more profitable?

Zura Bio's return on equity of -56.13% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -56.13% -50.15% Inhibrx Biosciences N/A -563.90% -83.48%

Zura Bio (ZURA) Competitors

$4.33 -0.18 (-3.99%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$4.35 +0.02 (+0.44%)

As of 05:37 AM Eastern

Compare

ZURA vs. NVAX, NTLA, ABSI, IMCR, and INBX

Should you buy Zura Bio stock or one of its competitors? Zura Bio's main competitors and comparable companies include Novavax (NVAX), Intellia Therapeutics (NTLA), Absci (ABSI), Immunocore (IMCR), and Inhibrx Biosciences (INBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zura Bio compare to Novavax?

Novavax (NASDAQ:NVAX) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Zura Bio has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Zura Bio	N/A	-56.13%	-50.15%

53.0% of Novavax shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 1.6% of Novavax shares are owned by company insiders. Comparatively, 12.4% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Novavax currently has a consensus price target of $14.00, indicating a potential upside of 32.70%. Zura Bio has a consensus price target of $17.00, indicating a potential upside of 292.61%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Novavax had 6 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for Novavax and 0 mentions for Zura Bio. Novavax's average media sentiment score of 0.68 beat Zura Bio's score of 0.09 indicating that Novavax is being referred to more favorably in the media.

Company	Overall Sentiment
Novavax	Positive
Zura Bio	Neutral

Novavax has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market.

Novavax has higher revenue and earnings than Zura Bio. Novavax is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.55	$440.30M	-$1.52	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A

Summary

Zura Bio beats Novavax on 8 of the 15 factors compared between the two stocks.

How does Zura Bio compare to Intellia Therapeutics?

Zura Bio (NASDAQ:ZURA) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Zura Bio has higher earnings, but lower revenue than Intellia Therapeutics. Zura Bio is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A
Intellia Therapeutics	$67.67M	25.53	-$412.69M	-$3.36	N/A

Zura Bio has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market.

Zura Bio currently has a consensus target price of $17.00, suggesting a potential upside of 292.61%. Intellia Therapeutics has a consensus target price of $20.98, suggesting a potential upside of 70.14%. Given Zura Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Zura Bio is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

Zura Bio has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Zura Bio's return on equity of -56.13% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-56.13%	-50.15%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

In the previous week, Intellia Therapeutics had 5 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for Intellia Therapeutics and 0 mentions for Zura Bio. Intellia Therapeutics' average media sentiment score of 0.29 beat Zura Bio's score of 0.09 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zura Bio	Neutral
Intellia Therapeutics	Neutral

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Intellia Therapeutics beats Zura Bio on 8 of the 15 factors compared between the two stocks.

How does Zura Bio compare to Absci?

Zura Bio (NASDAQ:ZURA) and Absci (NASDAQ:ABSI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Zura Bio has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Zura Bio's return on equity of -56.13% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-56.13%	-50.15%
Absci	-7,756.38%	-61.71%	-54.52%

Zura Bio has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, Absci has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market.

In the previous week, Absci had 5 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for Absci and 0 mentions for Zura Bio. Absci's average media sentiment score of 0.10 beat Zura Bio's score of 0.09 indicating that Absci is being referred to more favorably in the news media.

Company	Overall Sentiment
Zura Bio	Neutral
Absci	Neutral

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 52.1% of Absci shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by company insiders. Comparatively, 10.5% of Absci shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zura Bio presently has a consensus price target of $17.00, suggesting a potential upside of 292.61%. Absci has a consensus price target of $13.71, suggesting a potential upside of 40.80%. Given Zura Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Zura Bio is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Zura Bio has higher earnings, but lower revenue than Absci. Absci is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A
Absci	$2.80M	596.96	-$115.18M	-$0.80	N/A

Summary

Zura Bio beats Absci on 10 of the 16 factors compared between the two stocks.

How does Zura Bio compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Immunocore has higher revenue and earnings than Zura Bio. Immunocore is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$430.78M	3.77	-$35.51M	-$0.37	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A

Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market.

Zura Bio has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Zura Bio	N/A	-56.13%	-50.15%

Immunocore presently has a consensus target price of $56.38, indicating a potential upside of 78.74%. Zura Bio has a consensus target price of $17.00, indicating a potential upside of 292.61%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts clearly believe Zura Bio is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Immunocore had 2 more articles in the media than Zura Bio. MarketBeat recorded 2 mentions for Immunocore and 0 mentions for Zura Bio. Immunocore's average media sentiment score of 0.59 beat Zura Bio's score of 0.09 indicating that Immunocore is being referred to more favorably in the media.

Company	Overall Sentiment
Immunocore	Positive
Zura Bio	Neutral

84.5% of Immunocore shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 12.4% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Immunocore beats Zura Bio on 10 of the 15 factors compared between the two stocks.

How does Zura Bio compare to Inhibrx Biosciences?

Zura Bio (NASDAQ:ZURA) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Zura Bio's return on equity of -56.13% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-56.13%	-50.15%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

In the previous week, Inhibrx Biosciences had 9 more articles in the media than Zura Bio. MarketBeat recorded 9 mentions for Inhibrx Biosciences and 0 mentions for Zura Bio. Inhibrx Biosciences' average media sentiment score of 1.39 beat Zura Bio's score of 0.09 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Zura Bio	Neutral
Inhibrx Biosciences	Positive

Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A
Inhibrx Biosciences	N/A	N/A	-$140.05M	-$8.88	N/A

Zura Bio currently has a consensus price target of $17.00, suggesting a potential upside of 292.61%. Inhibrx Biosciences has a consensus price target of $197.50, suggesting a potential upside of 96.85%. Given Zura Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Zura Bio is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Zura Bio has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.66, suggesting that its share price is 266% more volatile than the broader market.

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 12.4% of Zura Bio shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Zura Bio beats Inhibrx Biosciences on 8 of the 13 factors compared between the two stocks.

Get Zura Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZURA vs. The Competition

Export

Metric	Zura Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$432.19M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-3.83	13.88	274.08	25.69
Price / Sales	N/A	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	3.14	15.40	10.47	6.32
Net Income	-$99.35M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-5.25%	-1.70%	-0.67%	0.17%
1 Month Performance	-31.27%	-6.17%	-3.17%	-3.27%
1 Year Performance	89.08%	30.67%	15.14%	5.58%

Zura Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZURA Zura Bio	2.7163 of 5 stars	$4.33 -4.0%	$17.00 +292.6%	+110.2%	$432.19M	N/A	N/A	40
NVAX Novavax	2.3518 of 5 stars	$10.83 +4.0%	$14.00 +29.3%	+21.7%	$1.72B	$1.12B	N/A	749
NTLA Intellia Therapeutics	2.8933 of 5 stars	$12.69 +3.8%	$20.98 +65.3%	-27.8%	$1.71B	$67.67M	N/A	377
ABSI Absci	2.898 of 5 stars	$10.71 +9.1%	$13.71 +28.1%	+274.6%	$1.69B	$2.80M	N/A	140	Analyst Forecast High Trading Volume
IMCR Immunocore	3.451 of 5 stars	$32.42 +0.7%	$56.38 +73.9%	-8.4%	$1.66B	$400.02M	N/A	524

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZURA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zura Bio (ZURA) Competitors